Structure Therapeutics Inc., a biopharmaceutical company based in San Francisco, has announced the initiation of a Phase 1 clinical study for its lead oral small molecule, ACCG-2671. This investigational drug aims to treat obesity by acting as an amylin receptor agonist. The study represents a significant step forward for the company, which focuses on developing novel therapeutics for metabolic diseases.
The Phase 1 study will assess the safety, tolerability, and pharmacokinetics of ACCG-2671 in healthy participants. Designed using the company’s advanced structure-based drug discovery platform, this oral medication is intended to deliver the established metabolic benefits associated with amylin biology in a convenient, once-daily dosage form.
Innovative Approach to Obesity Treatment
According to Xichen Lin, Ph.D., Chief Scientific Officer of Structure Therapeutics, the company believes that therapies based on amylin could play a crucial role in the evolving landscape of obesity treatment. “Powered by our differentiated GPCR structure-based drug discovery platform, we have efficiently advanced ACCG-2671 into the clinic as the industry’s most advanced oral small molecule amylin therapy,” Lin stated.
Preclinical data indicates that ACCG-2671 exhibits strong target engagement and significant weight loss effects. As a standalone treatment, it has shown promising results, and further weight reduction has been observed when combined with a glucagon-like peptide-1 receptor agonist (GLP-1 RA). The drug also demonstrates a favorable safety profile and pharmacokinetics suitable for once-daily administration.
Potential Impact on Patient Care
The development of ACCG-2671 highlights the potential for innovative therapies to reshape obesity management. With a focus on improving scalability, combinability, and patient access, Structure Therapeutics aims to establish this drug as a fundamental component of obesity treatment, whether used alone or in conjunction with other weight loss medications.
As the prevalence of obesity continues to rise globally, the need for effective therapeutic options remains critical. The initiation of this Phase 1 study marks an important milestone for Structure Therapeutics as it seeks to address the growing challenges associated with obesity and related metabolic conditions.
The results from this study could pave the way for further clinical trials and eventual commercialization, offering hope for millions struggling with obesity worldwide.
